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Background-—Recent evidence suggests that racial/ethnic differences in circulating levels of free or bioavailable 25-hydroxy
vitamin D (25[OH]D) rather than total 25(OH)D may explain apparent racial disparities in cardiovascular disease (CVD). We
prospectively examined black-white differences in the associations of total, free, and bioavailable 25(OH)D, vitamin D–binding
protein, and parathyroid hormone levels at baseline with incident CVD (including nonfatal myocardial infarction, nonfatal stroke,
and CVD death) in postmenopausal women.
Methods and Results-—We conducted a case-cohort study among 79 705 postmenopausal women, aged 50 to 79 years, who
were free of CVD at baseline in the WHI-OS (Women’s Health Initiative Observational Study). A subcohort of 1300 black and 1500
white participants were randomly chosen as controls; a total of 550 black and 1500 white women who developed incident CVD
during a mean follow-up of 11 years were chosen as cases. We directly measured total 25(OH)D, vitamin D–binding protein,
albumin, parathyroid hormone, and calculated free and bioavailable 25(OH)D. Weighted Cox proportional hazards models were
used to examine their associations with CVD risk. Although vitamin D–binding protein and total, free, and bioavailable 25(OH)D
were not signiﬁcantly associated with CVD risk in black or white women, a signiﬁcant positive association between parathyroid
hormone and CVD risk persisted in white women (hazard ratio comparing the highest quartile with the lowest, 1.37; 95% CI, 1.06–
1.77) but not in black women (hazard ratio comparing the highest quartile with the lowest, 1.12; 95% CI, 0.79–1.58), independent
of total, free, and bioavailable 25(OH)D or vitamin D–binding protein.
Conclusions-—Circulating levels of vitamin D biomarkers are not related to CVD risk in either white or black women. Higher
parathyroid hormone levels may be an independent risk factor for CVD in white women. ( J Am Heart Assoc. 2019;8:e011021.
DOI: 10.1161/JAHA.118.011021.)
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L ow levels of serum vitamin D have been associated withcardiovascular diseases (CVDs) and CVD risk factors,1,2
whereas mechanistic evidence supports a role of vitamin D in
cardiovascular system, including the renin-angiotensin system,
vascular inﬂammation, vascular calciﬁcation, and endothelial
cell function.2–4 The higher prevalence of low vitamin D levels
among black adults than among whites might be explained by
lower cutaneous vitamin D synthesis attributable to higher
melanin levels, lower intake of dairy products and other foods
fortiﬁed with vitamin D, or racial differences in vitamin D
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metabolism.5 Also, blacks have higher parathyroid hormone
(PTH) and experience a disproportionately higher burden of CVD
than do whites.5–7 Low total 25-hydroxy vitamin D (25[OH]D)
levels appeared to be a stronger risk factor for coronary heart
disease (CHD) in whites than blacks,8 as well as for stroke
mortality.9 However, because of limited data, evidence to
support such an association in white and black adults remains
inconclusive, and the speciﬁc thresholds of circulating 25(OH)D
for optimal cardiovascular health are unclear. Furthermore, free
or bioavailable 25(OH)D may be a better measure of vitamin D
activity than total 25(OH)D. Few studies have speciﬁcally
examined possible racial/ethnic differences in vitamin D–
binding protein (VDBP) or free or bioavailable vitamin D levels in
relation to racial disparities in CVD.
Previous studies have documented consistent and sub-
stantial white-black differences in both total 25(OH)D and
PTH.5 Existing data suggest that 25(OH)D threshold values for
vitamin D sufﬁciency that maximally suppress PTH secretion
may differ by race/ethnicity.5 PTH, independently or jointly
with vitamin D, plays a central role in calcium metabolism, the
renin-angiotensin system, endothelial function, and systemic
inﬂammation and may therefore inﬂuence cardiovascular
system.2 Furthermore, elevated PTH levels have been linked
to various cardiovascular outcomes, including hypertension,
cardiac hypertrophy, and CHD.10,11 A few studies have
speciﬁcally examined the joint associations of vitamin D
biomarkers and PTH on CVD risk12–17; however, the evidence
has been inconsistent and inconclusive.
To comprehensively examine racial/ethnic differences in
the associations of vitamin D biomarker and PTH with CVD
risk, we designed and conducted a prospective case-cohort
study in the multiethnic WHI-OS (Women’s Health Initiative
Observational Study) cohort to test the following speciﬁc aims
in white and black women, separately: (1) whether vitamin D
biomarkers, including plasma total 25(OH)D, VDBP, and/or
free or bioavailable 25(OH)D, independently predict the risk of
CVD; (2) whether PTH independently predicts the risk of CVD;
and (3) whether vitamin D biomarkers and PTH jointly predict
the risk of CVD.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request.
Study Population
Between September 1994 and December 1998, the WHI-OS
enrolled 93 676 postmenopausal women, aged 50 to 79 years,
at 40 clinical centers throughout the United States. Women of
all races and ethnicities were included, with a priority of
enrolling at least 20% racial/ethnic minority groups. At study
entry (ie, baseline), WHI-OS participants provided written
informed consent and completed questionnaires about dietary
habits, medical history, physical activity, socioeconomic status,
and use of medications and supplements. Each woman had a
physical examination, including direct measurement of weight,
height, and waist and hip circumference, and provided a blood
sample after an overnight fast of at least 12 hours.18 Women in
the WHI-OS provided written informed consent before partic-
ipation, and the study protocols and procedures were con-
ducted in accordance with recognized ethical guidelines and
were approved at the institutional review boards of each
participating center.
CVD End Point Ascertainment
CVD outcomes were ascertained by self-report using annual
questionnaires and documented by medical records. CHD was
deﬁned as acute myocardial infarction (MI) that required
overnight hospitalization and was conﬁrmed by electrocar-
diography, cardiac enzyme elevations, or coronary death.
Stroke diagnosis was based on the rapid onset of a neurologic
deﬁcit lasting >24 hours or until death, requiring hospitaliza-
tion and supported by imaging studies when available.19 The
incident CVD outcome included nonfatal MI, CHD death,
stroke (ischemic and hemorrhagic), and a composite of major
vascular events (nonfatal MI, nonfatal stroke, and CVD
mortality).
Clinical Perspective
What Is New?
• Controversy exists about the contributions of vitamin D
biomarkers to racial/ethnic disparities in cardiovascular
disease (CVD) because of lack of prospective evidence.
• This is, to our knowledge, the largest prospective study of
black-white differences in vitamin D biomarkers with regard
to CVD risk, which provided an in-depth evaluation of
interrelations of total 25-hydroxy vitamin D and parathyroid
hormone with CVD.
• None of these vitamin D biomarkers explained the higher
CVD risk of black women compared with white women in
this cohort, although our ﬁndings indicated that higher
parathyroid hormone may be an independent risk factor for
CVD in white women.
What Are the Clinical Implications?
• These ﬁndings from our observational study are timely and
can augment and complement ﬁndings from randomized
trials of the effect of vitamin D supplements on CVD and
other chronic disease outcomes.
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A Prospective Case-Cohort Study Design
We designed a case-cohort study of CVD within the WHI-OS for
efﬁciency and to preserve stored blood samples.20 We included
only black and non-Hispanic white women because of their
sufﬁcient numbers of incident CVD cases for testing our
hypotheses. After excluding those with a history of MI or stroke
or receiving dialysis at baseline, case identiﬁcation and
subcohort sampling were performed for the 79 705 eligible
women. CVD cases were women with conﬁrmed incidental
nonfatal MI, nonfatal stroke, or CVD death, as of the September
2013 database. A subcohort of 1415 black women was
randomly selected from 6794 eligible black participants. All
incident CVD cases in black women (not included in the
subcohort) were included, yielding a ﬁnal selection of 550
cases/1300 controls for black women. A subcohort of 1619
non-Hispanic white women was selected from 72 911 white
eligible participants. A random sample of 1381 incident cases
of CVD was selected from a total of 5941 eligible cases among
non-Hispanic white women, excluding those who were already
part of the subcohort sample, yielding a ﬁnal selection of 1500
cases/1500 controls for non-Hispanic white women.
Biomarker Measurement
Plasma concentrations of total 25(OH)D, VDBP, PTH, albumin,
and creatinine were measured by Dr Nader Rifai’s Clinical and
Epidemiologic Research Laboratory at Boston Children’s
Hospital (Boston, MA).21 Total 25(OH)D was measured by
an enzyme immunoassay from Immunodiagnostic Systems Inc
(Fountain Hills, AZ). VDBP was measured by a monoclonal
ELISA assay from R & D Systems (Minneapolis, MN). PTH was
measured by an electrochemiluminescence immunoassay on
the Roche E Modular system (Roche Diagnostics, Indianapolis,
IN). The lowest detection limit of this PTH assay is 1.2 pg/mL,
and the day-to-day imprecision values at concentrations of
44.3, 161, and 702 pg/mL are 7.1%, 5.0%, and 5.4%,
respectively. Albumin was measured by a colorimetric assay,
an automated dye-binding method using the Roche P Modular
system, and Roche Diagnostics reagents. The averaged
coefﬁcients of variation for each analyte were 6.95% for 25
(OH)D, 5.46% for VDBP, 3.46% for PTH, 0.74% for albumin, and
1.82% for creatinine. We calculated free 25(OH)D, bioavailable
25(OH)D, and glomerular ﬁltration rate (GFR). Free 25(OH)D
was calculated as follows: free 25(OH)D=(total 25[OH]D
levels)/[1+(691039albumin)+(791089VDBP)].22 Bioavailable
25(OH)D (free+albumin-bound fraction) was calculated using
equations adapted from that of Vermeulen et al.22 In addition,
we estimated GFR (eGFR) as a secondary measure of kidney
function, by the equation developed and validated from the
Modiﬁcation of Diet in Renal Disease Study, as recommended
by the National Kidney Foundation23: eGFR (in mL/min per
1.73 m2)=1869[creatinine (in mg/dL)1.1549age0.20390.742
(female)91.210 (black)].
Statistical Analysis
Differences in plasma total and free 25(OH)D, VDBP, and PTH
between cases and controls were examined using the Student
t test for white and black women, separately. Age- and
ethnicity-adjusted Pearson’s partial correlation coefﬁcients
were calculated to evaluate correlations between vitamin D
biomarkers among noncases.
All participants were categorized into quartiles according
to the distributions of each biomarker in the noncases. We
then calculated the hazard ratio (HR) of CVD events and the
corresponding 95% CI using a weighted Cox regression model
by designating the lowest quartile of each biomarker as the
reference group. The weight method was proposed by Barlow
et al as the inverse of the sampling probability of the
subcohort stratiﬁed by race.24 Age, clinical center, and race/
ethnicity were adjusted in model 1. The main models were
further adjusted for family history of CVD, educational levels,
alcohol intake, physical activity levels, cigarette smoking
status, postmenopausal hormone therapy use, eGFR, body
mass index (BMI), and season of blood draw (model 2).
Multivariable models were additionally adjusted for history of
hypertension, history of hypercholesterolemia, history of
diabetes mellitus, and statin use (model 3). Furthermore, we
included each vitamin D biomarker with PTH simultaneously in
the same model 3. In addition, we performed the same
models for individual CVD end points, including MI, stroke,
and CVD mortality. To explore the possible nonlinear dose-
response relationship between vitamin D biomarker and CVD
risk, we ﬁtted restricted cubic spline proportional hazards
regression models with 3 knots at 10, 50, and 90 percentiles
of the distribution of each biomarker, controlling for the same
covariates in model 3. We also examined whether the
associations of vitamin D biomarkers with CVD were modiﬁed
by race/ethnicity by adding interaction terms to model 2.
To evaluate the effect of the joint relationship of total 25
(OH)D and PTH on CVD risk, we divided the study population
into 4 subgroups according to 25(OH)D levels (<50 or
≥50 nmol/L) and PTH levels (<65 or ≥65 pg/mL). Compared
with women with 25(OH)D ≥50 nmol/L and PTH <65 pg/mL,
each subgroup-speciﬁc HR was estimated.
Finally, to explore potential effect modiﬁcations and to
assess the robustness of the results, we stratiﬁed the analysis
by age (<60 or ≥60 years), BMI (<25 or ≥25 kg/m2), physical
activity (<8 or ≥8 metabolic equivalent h/wk), cigarette
smoking status (current smoker or nonsmoker), alcohol
consumption (current drinker or nondrinker), hormone ther-
apy use (user or nonuser), seasons of blood draw (winter or
summer), family history of CVD (yes or no), history of diabetes
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mellitus (yes or no), history of hypertension (yes or no), statin
use (user or nonuser), and renal function (eGFR: <90 or
≥90 mL/min per 1.73 m2).
All P values were 2 tailed, using a signiﬁcance level of 0.05.
All analyses were performed using SAS, version 9.4 (SAS
Institute, Cary, NC).
Results
Compared with controls, CVD cases had signiﬁcantly higher
age, BMI, waist/hip ratio, and creatinine; had lower levels of
physical activity, current alcohol intake, albumin, and eGFR;
had less hormone therapy use; and were more likely to have a
family history of CVD and a history of diabetes mellitus,
hypertension, or high cholesterol among both white and black
women (Table 1). The mean levels of total 25(OH)D and VDBP
in white women were considerably higher than those in black
women, and their differences between cases and controls
were statistically signiﬁcant in white women only (P=0.0001
and P=0.02, respectively). Black women had higher PTH levels
than white women; differences in PTH between cases and
controls were signiﬁcant in both white (P<0.0001) and black
(P=0.03) women.
Among all noncases, total 25(OH)D was moderately
correlated with free 25(OH)D (r2=0.45) and bioavailable 25
(OH)D (r2=0.46) (Table 2). Free 25(OH)D was highly corre-
lated with bioavailable 25(OH)D (r2=0.99). Both free and
bioavailable 25(OH)D were inversely correlated with VDBP,
with r2 ranging from 0.58 to 0.59. The correlations were
similar between white and black women.
After adjustment for age, clinical center, and ethnicity, total
25(OH)D, VDBP, and PTH were inversely and signiﬁcantly
associated with CVD risk in all participants (Table 3). Further
adjustment for physical activity, cigarette smoking, alcohol
intake, educational levels, season of blood draw, and family
history of CVD attenuated these associations; the HRs
comparing the highest quartile with the lowest quartile were
0.68 (95% CI, 0.54–0.86; P for trend=0.001) for total 25(OH)D;
0.77 (95% CI, 0.60–0.99; P for trend=0.006) for VDBP; and 1.45
(95% CI, 1.19–1.76; P for trend <0.0001) for PTH. Additionally
controlling for BMI, postmenopausal hormone therapy use,
history of hypertension, diabetesmellitus, high cholesterol, and
statin use, and eGFR levels attenuated the associations of total
25(OH)D and VDBP toward the null but did not materially alter
the results for PTH. These associations were similar in white
women; none of these biomarkers was signiﬁcantly associated
with CVD among black women. When each vitamin D biomarker
was mutually adjusted, PTH remained signiﬁcantly associated
with CVD in all women and white women (Table 3).
In the spline regression analysis, the nonlinear relationship
between total 25(OH)D and CVD was apparent among white
and black women (P for nonlinearity=0.02 and 0.09, respec-
tively) (Figure[A]). The inverse association between total 25
(OH)D levels and CVD risk was only seen among women with
high levels of 25(OH)D (approximately >55 ng/mL for white
women and >35 ng/mL for black women). A nonlinear
relationship between PTH and CVD was also observed in
both white and black women (P for nonlinearity=0.001 and
0.02, respectively) (Figure[B]). The higher PTH levels were
associated with increased risk of CVD in women with PTH
levels >40 pg/mL for white women and >65 pg/mL for black
women. Such positive associations of PTH with CVD seemed
stronger in white women than in black women. However, the
P values for the interaction of race/ethnicity with 25(OH)D
and PTH were not statistically signiﬁcant for CVD (P for
interaction >0.05). In addition, free and bioavailable 25(OH)D
showed a reverse J-shaped relationship with CVD risk among
white women (P for nonlinearity <0.0001 for both; Figures S1
and S2). There were no associations between VDBP and CVD
in white and black women (P for nonlinearity >0.05 for both)
(Figure S3).
For the joint associations with women with high 25(OH)D
and low PTH as the referent group, we found that high levels
of PTH (≥65 pg/mL) were consistently and signiﬁcantly
associated with increased CVD risk, regardless of total 25
(OH)D levels; multivariate-adjusted HRs were 1.87 (95% CI,
1.33–2.62) for 25(OH)D <50 nmol/L and 1.61 (95% CI, 1.05–
2.49) for 25(OH)D ≥50 nmol/L (Table 4). The association was
slightly stronger among women with high PTH and low 25(OH)
D levels, indicating a possible synergistic association between
25(OH)D and PTH with CVD risk. Similar patterns were
observed for white women, but not for black women.
We found no signiﬁcant associations between baseline 25
(OH)D levels and each individual CVD outcome, including MI,
stroke, and CVD mortality (Tables S1 through S3). However,
PTH was signiﬁcantly and inversely associated with CVD
mortality; the multivariate-adjusted HR was 1.17 (95% CI,
1.08–1.26; P for linear trend=0.02). The positive associations
remained similarly signiﬁcant among white women only.
Finally, we observed no signiﬁcant interactions by age, BMI,
physical activity level, alcohol consumption, cigarette smoking,
hormone therapy use, season of blood draw, family history of
CVD, history of diabetesmellitus, history of hypertension, statin
use, or renal function on the associations of vitamin D
biomarkers and PTH with CVD risk (data not shown).
Discussion
In this large, prospective case-cohort study performed within
an ethnically diverse cohort of US postmenopausal women
without apparent CVD at baseline, we found no signiﬁcant
associations between VDBP or total, free, or bioavailable 25
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Table 1. Baseline Characteristics by Ethnicity and CVD Status in a Case-Cohort Study From the WHI-OS
Variables
US White Women US Black Women
Cases Controls
P Value
Cases Controls
P Value(n=1500) (n=1500) (n=550) (n=1300)
Age, y 69 (64, 73) 63 (57, 68) <0.0001 65 (59, 71) 61 (56, 66) <0.0001
BMI, kg/m2 27.96.2 26.85.4 <0.0001 31.36.8 30.66.5 0.04
Waist/hip ratio, cm 0.830.08 0.800.07 <0.0001 0.840.1 0.820.08 <0.0001
Family history of CVD, n (%) 853 (60.3) 741 (52.2) <0.0001 242 (48.8) 498 (42.4) 0.02
Physical activity, MET h/wk 8 (2.5, 17.1) 10.5 (3.8, 21) <0.0001 5 (0.8, 13.9) 6.5 (1.3, 15.8) 0.06
Sitting time, n (%)
<5 h 481 (32.3) 515 (34.5) 0.57 222 (41.1) 498 (38.8) 0.28
5–10 h 643 (43.2) 603 (40.4) 188 (34.8) 451 (35.1)
≥10 h 366 (24.6) 375 (25.1) 130 (24.1) 335 (26.1)
Smoking status, n (%)
Never 705 (48.0) 720 (48.6) 0.02 256 (47.3) 631 (49.3) 0.04
Past 654 (44.5) 684 (46.2) 203 (37.5) 515 (40.2)
Current 110 (7.5) 77 (5.2) 82 (15.2) 134 (10.5)
Alcohol status, n (%)
Never 166 (11.1) 129 (8.7) 0.01 102 (18.7) 248 (19.3) <0.0001
Past 328 (22) 253 (17) 208 (38.1) 402 (31.2)
Current 995 (66.8) 1103 (74.2) 236 (43.2) 637 (59.5)
<1 Drink/d 792 (53.2) 911 (61.3) 219 (40.1) 567 (44.1)
≥1 Drink/d 203 (13.6) 192 (12.9) 17 (3.1) 70 (5.4)
History of diabetes mellitus, n (%) 159 (16.7) 84 (7.7) <0.0001 84 (29.1) 115 (18.4) <0.0001
History of hypertension, n (%) 747 (50.7) 414 (28.1) 366 (68.0) 679 (52.8)
Untreated hypertension, n (%) 173 (11.7) 109 (7.4) <0.0001 57 (10.6) 122 (9.5) <0.0001
Treated hypertension, n (%) 574 (39.0) 305 (20.7) 309 (57.4) 557 (43.3)
History of high cholesterol, n (%) 274 (18.6) 209 (14.2) 0.03 103 (19.4) 194 (15.2) 0.001
Hormone therapy use, n (%) 843 (56.2) 961 (64.1) 198 (36.2) 537 (41.2)
Past use 276 (18.4) 230 (15.3) 0.02 77 (14.1) 170 (13.1) <0.0001
Current use 567 (37.8) 731 (48.8) 121 (22.1) 367 (28.3)
Statin use, n (%) 318 (21.2) 214 (14.3) 0.04 99 (18) 186 (14.3) <0.0001
Educational levels, n (%)
High school graduate/GED or less 357 (23.8) 306 (20.4) 0.46 158 (28.7) 344 (26.5) <0.0001
Post high school 597 (39.8) 514 (34.3) 208 (37.8) 486 (37.4)
College graduate or higher 546 (36.4) 680 (45.3) 184 (33.5) 470 (36.2)
Geographical latitudes, n (%)
Southern: <35° north 415 (27.7) 447 (29.8) 0.15 191 (34.7) 426 (32.8) 0.25
Middle: 35°–40° north 427 (28.5) 438 (29.2) 196 (35.6) 428 (32.9)
Northern: >40° north 658 (43.9) 615 (41.0) 163 (29.6) 446 (34.3)
Seasons for blood drawing, n (%)
Spring 433 (28.9) 437 (29.3) 0.43 150 (27.3) 382 (29.8) 0.95
Summer 422 (28.2) 432 (28.9) 143 (26) 348 (27.1)
Autumn 336 (22.4) 325 (21.8) 122 (22.2) 281 (21.9)
Winter 306 (20.4) 300 (20.1) 134 (24.4) 272 (21.2)
Continued
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(OH)D and incident CVD in either black or white women.
None of these vitamin D biomarkers explained the higher
CVD risk of black women compared with white women in
this cohort, although our ﬁndings indicated that higher PTH
may be an independent risk factor for CVD in white women,
regardless of vitamin D biomarkers as well as known CVD
risk factors.
A large body of observational studies have linked low
total 25(OH)D (<60 nmol/L) to increased risk for CVD,1,2,4
although previous work has mainly assessed total 25(OH)
D. Accumulating evidence suggests that free and bioavail-
able 25(OH)D may better reﬂect the bioactivities of vitamin
D in tissues, particularly in bone metabolism.25 However,
there remains much debate over the validity of novel
vitamin D biomarkers, especially VDBP, for assessing
vitamin D status and/or physiologic functions in various
populations, given mixed results on the relationship of
VDBP and albumin or calculated free vitamin D to
CVD.26,27
In our study, VDBP was also measured using a monoclonal
ELISA, which has been criticized for being subject to
differential binding by genotype.28 As a tissue-speciﬁc and
polymorphic glycoprotein,29 VDBP has several isoforms with
different distributions and binding afﬁnities by race. In
addition, the amounts of circulating vitamin D metabolites
available for target tissues after binding to VDBP also appear
to vary by race.28 Nevertheless, our prospective ﬁndings of
the modest association between elevated VDBP and low CVD
risk did not persist after adjusting for known CVD risk factors.
In a multiethnic case-cohort study within the MESA (Multi-
Ethnic Study of Atherosclerosis) involving 538 CHD cases
over 12 years of follow-up and 999 randomly selected
controls, VDBP measured using the liquid chromatography–
tandem mass spectrometry method did not vary substantially
by race or ethnicity and was associated with CHD events in all
racial and ethnic groups. Total and bioavailable 25(OH)D were
associated with incident CHD among whites but not among
blacks.26 Taken together, the evidence suggests that
Table 1. Continued
Variables
US White Women US Black Women
Cases Controls
P Value
Cases Controls
P Value(n=1500) (n=1500) (n=550) (n=1300)
Ultraviolet B, n (%)
0.4–0.5 W/m2 318 (21.2) 331 (22.1) 0.06 160 (29.1) 450 (34.6) 0.58
0.5–1.0 W/m2 661 (44.1) 633 (42.2) 217 (39.5) 456 (35.1)
1.1–1.9 W/m2 521 (34.7) 536 (35.7) 173 (31.5) 394 (30.3)
Vitamin D biomarkers
Total 25(OH)D levels, nmol/L 62.120.2 64.920.2 0.0001 45.316.4 45.416.3 0.90
Free 25(OH)D levels, nmol/L 8.293.94 8.453.82 0.28 10.295.05 10.295.27 1.00
Bioavailable 25(OH)D, nmol/L 3.261.57 3.351.53 0.10 3.941.94 4.032.06 0.38
VDBP levels, ng/mL 240.677.4 247.178.6 0.02 136.770.8 138.369.4 0.66
PTH, pg/mL 38.8 (30.5, 48.9) 35.6 (28.4, 44.2) <0.0001 41.8 (32.6, 55) 40.2 (31.4, 51.7) 0.03
Albumin, g/dL 4.340.25 4.380.24 <0.0001 4.240.29 4.330.25 <0.0001
CVD core biomarkers
Creatinine, mg/dL 0.750.18 0.730.13 <0.0001 0.860.32 0.790.17 <0.0001
eGFR, ml/min/1.73m2 80.718.5 83.816.8 <0.0001 87.224.1 93.621.5 <0.0001
hs-CRP, mg/L 3 (1.4, 6.8) 2.2 (0.9, 4.9) <0.0001 4.2 (1.9, 9.4) 3.3 (1.4, 7.2) <0.0001
Glucose, mg/dL 95 (89, 104) 93 (88, 99) <0.0001 97 (88, 118) 94 (87, 105) <0.0001
Insulin, lIU/mL 7.9 (5.3, 12.2) 6.6 (4.6, 10) <0.0001 9.4 (5.9, 14.5) 9.1 (5.6, 13.7) 0.11
HOMA-%B 85.9 (59.9, 125) 81.6 (57.3, 117) 0.02 87.8 (57.9, 141) 98.8 (63.1, 148) 0.01
HOMA-IR 1.9 (1.2, 3.1) 1.5 (1, 2.4) <0.0001 2.4 (1.4, 4.2) 2.1 (1.3, 3.6) 0.002
Continuous variables are presented as meanSD, or, for non-normally distributed variables, median (interquartile range). 25(OH)D indicates 25-hydroxy vitamin D; BMI, body mass index;
CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration rate; GED, General Education Development; HOMA-%B, homeostatic model assessment of pancreatic b-cell function;
HOMA-IR, homeostatic model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; MET, metabolic equivalent; PTH, parathyroid hormone; VDBP, vitamin D–binding
protein; WHI-OS, Women’s Health Initiative Observational Study.
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differences in VDBP, regardless of assay method, may not
explain signiﬁcant racial and ethnic differences in the
association between total 25(OH)D and CVD.
Our results conﬁrm the consistent and substantial white-
black differences in total 25(OH)D and PTH,5 but do not
support the hypothesis that racial/ethnic differences in total
25(OH)D contribute signiﬁcantly to black-white disparities in
CVD. In our study, total 25(OH)D was modestly correlated
with PTH (r2=0.29) in white and black women, consistent
with most previous studies.5,12,30 Previous studies have
documented a consistent association between elevated PTH
levels and increased risk of CVD outcomes.10,11 Systematic
reviews and meta-analyses of prospective studies showed
evidence of substantial between-study heterogeneity in
previous studies, such as differences in participant charac-
teristics, PTH assays, baseline PTH levels, CVD ascertain-
ments and end points, and comorbid chronic kidney disease,
but none of them inﬂuenced the overall association between
PTH excess and CVD risk.10,11 However, it remains unclear
whether the PTH-CVD relationship is independent of 25(OH)D
Table 2. Age-Adjusted Spearman Correlation Coefﬁcients for Vitamin D Biomarkers and CVD Biomarkers Among Controls
Biomarkers Total 25(OH)D Free 25(OH)D
Bioavailable
25(OH)D VDBP PTH Creatinine hs-CRP Glucose Insulin
All noncases (n=2800)
Total 25(OH)D 1 0.45 0.46 0.34 0.29 0.07 0.07 0.15 0.09
Free 25(OH)D 1 0.99 0.59 0.15 0.04 0.04 0.02* 0.02*
Bioavailable 25(OH)D 1 0.58 0.15 0.04 0.06 0.02* 0.02*
VDBP 1 0.09 0.1 0.001* 0.12 0.05
PTH 1 0.27 0.05 0.04 0.07
Creatinine 1 0.04 0.02* 0.07
hs-CRP 1 0.13 0.06
Glucose 1 0.23
Insulin 1
US white noncases (n=1500)
Total 25(OH)D 1 0.60 0.60 0.16 0.27 0.02* 0.05 0.15 0.16
Free 25(OH)D 1 0.99 0.59 0.17 0.02* 0.08 0.06 0.03*
Bioavailable 25(OH)D 1 0.59 0.17 0.02* 0.11 0.06 0.05
VDBP 1 0.03* 0.003* 0.08 0.09 0.10
PTH 1 0.22 0.06 0.06 0.08
Creatinine 1 0.03* 0.07 0.02*
hs-CRP 1 0.12 0.15
Glucose 1 0.34
Insulin 1
US black noncases (n=1300)
Total 25(OH)D 1 0.65 0.65 0.08 0.27 0.005* 0.04* 0.07 0.04*
Free 25(OH)D 1 0.99 0.61 0.19 0.007* 0.03* 0.03* 0.04*
Bioavailable 25(OH)D 1 0.6 0.19 0.02* 0.06 0.04* 0.04*
VDBP 1 0.01* 0.02* 0.02* 0.02* 0.04*
PTH 1 0.29 0.009* 0.009* 0.06
Creatinine 1 0.02* 0.03* 0.07
hs-CRP 1 0.13 0.03*
Glucose 1 0.21
Insulin 1
25(OH)D indicates 25-hydroxy vitamin D; CVD, cardiovascular disease; hs-CRP, high-sensitivity C-reactive protein; PTH, parathyroid hormone; VDBP, vitamin D–binding protein.
*Indicates nonsigniﬁcant, P>0.05.
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Table 3. HRs for Risk of CVD by Levels of Vitamin D Biomarkers Among Postmenopausal Women
Variable Model
HR (95% CI)
P Value
for Trend HRper-SD (95% CI)*Quartile 1 Quartile 2 Quartile 3 Quartile 4
Total 25(OH)D,
ranges, nmol/L
11.9–40.0 40.0–53.3 53.3–68.8 68.8–228
All participants
(n=4808)
1† 1 (Referent) 0.75 (0.62–0.92) 0.68 (0.56–0.83) 0.61 (0.49–0.74) <0.0001 0.84 (0.78–0.91)
2‡ 1 (Referent) 0.86 (0.69–1.07) 0.79 (0.63–0.99) 0.79 (0.62–1.00) 0.07 0.92 (0.85–1.01)
3§ 1 (Referent) 0.90 (0.72–1.12) 0.89 (0.71–1.12) 0.91 (0.72–1.15) 0.55 0.97 (0.89–1.06)
3+PTH 1 (Referent) 0.94 (0.76–1.18) 0.93 (0.73–1.17) 0.98 (0.77–1.26) 0.96 1.00 (0.91–1.09)
US white
women
(n=2967)
1† 1 (Referent) 0.76 (0.61–0.95) 0.67 (0.53–0.84) 0.68 (0.54–0.85) 0.001 0.84 (0.77–0.92)
2‡ 1 (Referent) 0.78 (0.61–1.00) 0.76 (0.58–0.98) 0.83 (0.64–1.07) 0.22 0.91 (0.83–1.01)
3§ 1 (Referent) 0.87 (0.68–1.12) 0.89 (0.69–1.16) 0.95 (0.73–1.25) 0.86 0.97 (0.88–1.07)
3+PTH 1 (Referent) 0.88 (0.68–1.13) 0.93 (0.71–1.21) 1.02 (0.78–1.34) 0.73 1.00 (0.90–1.11)
US black
women
(n=1841)
1† 1 (Referent) 0.87 (0.65–1.16) 0.82 (0.61–1.10) 0.73 (0.55–0.98) 0.04 0.88 (0.77–1.01)
2‡ 1 (Referent) 0.97 (0.69–1.34) 0.97 (0.69–1.36) 0.94 (0.67–1.32) 0.74 0.99 (0.85–1.17)
3§ 1 (Referent) 1.04 (0.74–1.44) 1.09 (0.77–1.53) 1.02 (0.73–1.44) 0.84 1.02 (0.87–1.19)
3+PTH 1 (Referent) 1.05 (0.75–1.46) 1.10 (0.78–1.56) 1.07 (0.75–1.54) 0.67 1.05 (0.89–1.24)
Free 25(OH)D,
ranges, nmol/L
1.63–6.10 6.10–8.22 8.23–11.3 11.3–44.7
All participants
(n=4802)
1† 1 (Referent) 0.91 (0.76–1.09) 0.84 (0.70–1.01) 0.91 (0.76–1.10) 0.33 0.95 (0.89–1.02)
2‡ 1 (Referent) 0.86 (0.67–1.11) 0.99 (0.77–1.27) 0.95 (0.73–1.24) 0.98 1.01 (0.93–1.09)
3§ 1 (Referent) 1.08 (0.89–1.32) 1.03 (0.84–1.26) 1.06 (0.86–1.31) 0.70 1.01 (0.94–1.09)
3+PTH 1 (Referent) 1.05 (0.85–1.30) 1.09 (0.88–1.34) 1.32 (1.07–1.63) 0.36 1.03 (0.95–1.12)
US white
women
(n=2965)
1† 1 (Referent) 0.79 (0.63–0.99) 0.80 (0.64–1.00) 0.85 (0.68–1.07) 0.27 0.95 (0.86–1.05)
2‡ 1 (Referent) 1.26 (0.78–2.03) 0.99 (0.73–1.33) 1.15 (0.82–1.62) 0.50 1.02 (0.91–1.15)
3§ 1 (Referent) 0.88 (0.68–1.14) 1.09 (0.84–1.40) 0.97 (0.75–1.26) 0.86 1.03 (0.92–1.16)
3+PTH 1 (Referent) 0.91 (0.70–1.18) 1.12 (0.86–1.45) 1.05 (0.80–1.37) 0.48 1.06 (0.95–1.19)
US black
women
(n=1837)
1† 1 (Referent) 1.26 (0.83–1.91) 0.97 (0.75–1.27) 1.04 (0.78–1.39) 0.96 0.97 (0.89–1.06)
2‡ 1 (Referent) 1.26 (0.78–2.03) 0.99 (0.73–1.33) 1.15 (0.82–1.62) 0.50 1.00 (0.90–1.10)
3§ 1 (Referent) 1.07 (0.67–1.72) 0.96 (0.71–1.30) 1.09 (0.77–1.52) 0.67 0.99 (0.89–1.10)
3+PTH 1 (Referent) 1.08 (0.67–1.73) 0.98 (0.72–1.33) 1.13 (0.79–1.61) 0.53 1.00 (0.90–1.11)
Bioavailable 25(OH)D,
ranges, nmol/L
0.59–2.38 2.38–3.25 3.25–4.45 4.45–16.6
All participants
(n=4802)
1† 1 (Referent) 0.89 (0.75–1.06) 0.86 (0.72–1.03) 0.86 (0.71–1.03) 0.96 0.93 (0.87–1.00)
2‡ 1 (Referent) 1.00 (0.82–1.21) 0.99 (0.81–1.21) 0.96 (0.78–1.19) 0.73 0.99 (0.92–1.07)
3§ 1 (Referent) 1.03 (0.85–1.25) 1.05 (0.86–1.29) 0.97 (0.79–1.20) 0.78 0.99 (0.92–1.07)
3+PTH 1 (Referent) 1.06 (0.86–1.29) 1.08 (0.88–1.33) 1.02 (0.82–1.27) 0.83 1.01 (0.94–1.10)
US white
women
(n=2965)
1† 1 (Referent) 0.81 (0.65–1.02) 0.81 (0.65–1.02) 0.89 (0.71–1.12) 0.49 0.94 (0.85–1.04)
2‡ 1 (Referent) 0.95 (0.74–1.21) 0.98 (0.76–1.26) 1.07 (0.82–1.39) 0.55 1.01 (0.90–1.14)
3§ 1 (Referent) 1.01 (0.79–1.3) 1.12 (0.87–1.45) 1.09 (0.84–1.42) 0.43 1.02 (0.92–1.15)
3+PTH 1 (Referent) 1.05 (0.81–1.35) 1.16 (0.89–1.51) 1.18 (0.90–1.55) 0.19 1.05 (0.94–1.18)
US black
women
(n=1837)
1† 1 (Referent) 1.00 (0.75–1.34) 0.88 (0.65–1.18) 0.91 (0.68–1.22) 0.45 0.94 (0.86–1.02)
2‡ 1 (Referent) 1.06 (0.76–1.46) 0.92 (0.65–1.29) 1.03 (0.73–1.45) 0.98 0.97 (0.87–1.08)
3§ 1 (Referent) 0.98 (0.71–1.35) 0.89 (0.64–1.25) 0.96 (0.69–1.35) 0.79 0.96 (0.86–1.06)
3+PTH 1 (Referent) 1.00 (0.72–1.39) 0.91 (0.64–1.28) 1.00 (0.70–1.42) 0.94 0.97 (0.86–1.08)
VDBP, ranges, ng/mL 26.1–111 111–196 196–262 262–594
Continued
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Table 3. Continued
Variable Model
HR (95% CI)
P Value
for Trend HRper-SD (95% CI)*Quartile 1 Quartile 2 Quartile 3 Quartile 4
All participants
(n=4811)
1† 1 (Referent) 1.00 (0.81–1.23) 0.90 (0.72–1.11) 0.76 (0.60–0.95) 0.002 0.90 (0.83–0.97)
2‡ 1 (Referent) 1.06 (0.84–1.33) 0.98 (0.77–1.25) 0.85 (0.65–1.10) 0.06 0.93 (0.85–1.01)
3§ 1 (Referent) 1.12 (0.89–1.42) 1.05 (0.81–1.34) 0.93 (0.71–1.21) 0.20 0.96 (0.88–1.05)
3+PTH 1 (Referent) 1.13 (0.89–1.43) 1.03 (0.80–1.33) 0.92 (0.71–1.21) 0.18 0.96 (0.88–1.05)
US white
women
(n=2970)
1† 1 (Referent) 0.91 (0.73–1.14) 0.85 (0.68–1.07) 0.78 (0.62–0.98) 0.03 0.90 (0.82–0.99)
2‡ 1 (Referent) 0.96 (0.75–1.22) 0.88 (0.69–1.14) 0.82 (0.63–1.06) 0.10 0.91 (0.82–1.02)
3§ 1 (Referent) 0.91 (0.71–1.17) 0.90 (0.70–1.16) 0.87 (0.67–1.14) 0.32 0.94 (0.85–1.05)
3+PTH 1 (Referent) 0.88 (0.68–1.14) 0.88 (0.69–1.14) 0.87 (0.67–1.13) 0.31 0.94 (0.84–1.05)
US black
women
(n=1841)
1† 1 (Referent) 0.94 (0.7–1.25) 1.00 (0.75–1.33) 0.89 (0.69–1.08) 0.22 0.92 (0.81–1.06)
2‡ 1 (Referent) 0.94 (0.68–1.30) 1.04 (0.75–1.45) 0.87 (0.62–1.24) 0.61 0.99 (0.84–1.17)
3§ 1 (Referent) 0.93 (0.67–1.30) 1.08 (0.78–1.50) 0.95 (0.67–1.34) 0.99 1.04 (0.88–1.22)
3+PTH 1 (Referent) 0.93 (0.66–1.30) 1.07 (0.77–1.49) 0.94 (0.66–1.34) 0.96 1.04 (0.88–1.23)
PTH, ranges, pg/mL 2.36–29.7 29.7–37.4 37.4–47.6 47.6–491
All participants
(n=4806)
1† 1 (Referent) 1.08 (0.89–1.30) 1.22 (1.01–1.46) 1.55 (1.29–1.87) <0.0001 1.17 (1.11–1.23)
2‡ 1 (Referent) 1.01 (0.82–1.25) 1.12 (0.92–1.38) 1.41 (1.15–1.73) 0.0002 1.17 (1.11–1.25)
3§ 1 (Referent) 1.05 (0.85–1.30) 1.09 (0.88–1.33) 1.30 (1.06–1.60) 0.008 1.12 (1.06–1.19)
3+Total 25(OH)D 1 (Referent) 1.04 (0.84–1.29) 1.07 (0.87–1.32) 1.28 (1.04–1.59) 0.01 1.12 (1.05–1.19)
3+Free 25(OH)D 1 (Referent) 1.05 (0.85–1.30) 1.09 (0.88–1.34) 1.32 (1.07–1.63) 0.007 1.12 (1.06–1.19)
3+Bioavailable
25(OH)D
1 (Referent) 1.06 (0.86–1.29) 1.08 (0.88–1.33) 1.02 (0.82–1.27) 0.01 1.12 (1.05–1.19)
3+VDBP 1 (Referent) 1.05 (0.85–1.30) 1.09 (0.88–1.34) 1.30 (1.06–1.60) 0.007 1.12 (1.05–1.19)
US white
women
(n=2969)
1† 1 (Referent) 1.07 (0.84–1.36) 1.11 (0.88–1.41) 1.55 (1.23–1.94) <0.0001 1.20 (1.12–1.28)
2‡ 1 (Referent) 1.11 (0.86–1.45) 1.03 (0.78–1.34) 1.48 (1.15–1.90) 0.001 1.18 (1.11–1.27)
3§ 1 (Referent) 1.22 (0.93–1.60) 1.07 (0.82–1.40) 1.43 (1.11–1.84) 0.01 1.13 (1.05–1.21)
3+Total 25(OH)D 1 (Referent) 1.21 (0.92–1.59) 1.05 (0.80–1.38) 1.39 (1.07–1.81) 0.02 1.12 (1.04–1.21)
3+Free 25(OH)D 1 (Referent) 1.23 (0.94–1.61) 1.08 (0.83–1.42) 1.46 (1.13–1.89) 0.007 1.13 (1.05–1.21)
3+Bioavailable
25(OH)D
1 (Referent) 1.22 (0.93–1.6) 1.08 (0.82–1.41) 1.44 (1.12–1.87) 0.008 1.13 (1.05–1.21)
3+VDBP 1 (Referent) 1.22 (0.93–1.59) 1.07 (0.82–1.40) 1.43 (1.11–1.84) 0.008 1.13 (1.05–1.21)
US black
women
(n=1837)
1† 1 (Referent) 1.16 (0.85–1.56) 1.30 (0.97–1.75) 1.50 (1.12–2.01) 0.005 1.19 (1.05–1.34)
2‡ 1 (Referent) 1.12 (0.79–1.57) 1.24 (0.89–1.74) 1.37 (0.97–1.92) 0.07 1.17 (1.03–1.33)
3§ 1 (Referent) 1.01 (0.71–1.43) 1.12 (0.79–1.58) 1.24 (0.88–1.74) 0.16 1.13 (1.05–1.21)
3+Total 25(OH)D 1 (Referent) 1.02 (0.72–1.44) 1.14 (0.80–1.63) 1.27 (0.89–1.82) 0.13 1.12 (1.04–1.21)
3+Free 25(OH)D 1 (Referent) 1.02 (0.72–1.44) 1.13 (0.80–1.60) 1.26 (0.89–1.78) 0.15 1.13 (1.05–1.21)
3+Bioavailable
25(OH)D
1 (Referent) 1.00 (0.71–1.42) 1.11 (0.78–1.56) 1.22 (0.86–1.73) 0.20 1.13 (1.05–1.21)
3+VDBP 1 (Referent) 1.00 (0.70–1.41) 1.12 (0.79–1.58) 1.23 (0.87–1.73) 0.16 1.13 (1.05–1.21)
25(OH)D indicates 25-hydroxy vitamin D; CVD, cardiovascular disease; HR, hazard ratio; PTH, parathyroid hormone; VDBP, vitamin D–binding protein.
*HRs represent per-SD increases in biomarker measures among control participants.
†Model 1 adjusted for age, clinical center, and race/ethnicity (for all participants).
‡Model 2 further adjusted for family history of CVD, educational levels, alcohol intake, physical activity levels, cigarette smoking status, postmenopausal hormone therapy use, estimated
glomerular ﬁltration rate, body mass index, and seasons of blood draw.
§Model 3 further adjusted for history of hypertension, history of hypercholesterolemia, history of diabetes mellitus, and statin use.
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Figure. Race/ethnicity-speciﬁc associations of total 25-hydroxy vitamin D (25[OH]D) and parathyroid hormone (PTH) with cardiovascular
disease (CVD) events. A, Total 25(OH)D and CVD events. B, PTH and CVD events. Associations were estimated by proportional hazards
regression–based restricted cubic spline analyses among white and black women, separately. We calculated restricted cubic spline with 3 ﬁxed
knots at 10%, 50%, and 90% percentiles based on the distribution of each biomarker level. Solid lines with gray areas indicate the hazard ratios
(HRs) and 95% CIs. The model was adjusted for age, clinical center, race/ethnicity, body mass index, family history of CVD, educational levels,
alcohol intake, physical activity levels, cigarette smoking status, postmenopausal hormone therapy use, estimated glomerular ﬁltration rate, and
season of blood draw.
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because of limited data. Our positive ﬁndings of the PTH-CVD
relationship among US white women are consistent with the
LASA (Longitudinal Aging Study Amsterdam) (predominantly
white men and women)14 and a US Utah healthcare
population12 showing that PTH was a signiﬁcant predictor
for CVD independent of 25(OH)D. Similarly, the BRHS (British
Regional Heart Study), comprising predominantly whites,
reported that elevated PTH, but not 25(OH)D, was associated
with increased risk of heart failure in British older men with
and without CVD.13 Our ﬁndings are less consistent with the
Hoorn Study, a Netherlands population-based study of white
men and women in which high PTH levels were signiﬁcantly
associated with CVD mortality, but not independent of 25(OH)
D levels.17 In contrast, PTH did not predict CVD mortality in a
population of middle-aged and older European men in the
EMAS (European Male Aging Study).16 The ARIC (Atheroscle-
rosis Risk in Communities) Study in the United States found
no association of PTH with CHD regardless of renal status or
25(OH)D levels, potentially because of random measurement
error caused by time-dependent deterioration of ARIC Study
samples.15
The interactions of the vitamin D/PTH endocrine system
are complex. PTH, independently or jointly with vitamin D,
plays a central role in calcium metabolism, the renin-
angiotensin system, endothelial function, and systemic
inﬂammation and may therefore inﬂuence CVD risk.2,3 Our
results indicate that further investigation of joint associations
of vitamin D and PTH with clinically signiﬁcant end points is
important for a better understanding of their relationship with
CVD and racial disparities in CVD.
The strengths of our study include its prospective design,
the use of the large and well-characterized cohort of white
and black women, detailed measures of potential con-
founders, rigorous adjudication of incident CVD cases, and a
comprehensive panel of vitamin D biomarkers. Nonetheless,
the present study has several limitations. First, VDBP was
measured using a monoclonal ELISA rather than a mass
spectrometry assay, although the presumed gold standard
mass spectrometry method for directly measuring polymor-
phic VDBP remains to be validated across diverse popula-
tions. Second, single measurement of vitamin D biomarkers
with varying coefﬁcients of variation might have biased the
results toward the null. However, previous validation data in
large cohorts, similar to those of the WHI-OS, have found
that a single 25(OH)D measurement is fairly reproducible
over 2 to 11 years and reasonably reﬂects long-term vitamin
D status.15,27 Third, we cannot discount that some associ-
ations may be affected by multiple tests and/or residual
confounding. It is also possible that the lack of statistically
signiﬁcant interactions by race/ethnicity and racial
Table 4. HRs for Risk of CVD by Total 25(OH)D and PTH Levels Among Postmenopausal Women
Model
Total Cases/
Controls
PTH <65 pg/mL PTH ≥65 pg/mL
25(OH)D ≥50 nmol/L 25(OH)D <50 nmol/L 25(OH)D ≥50 nmol/L 25(OH)D <50 nmol/L
All women
No. (cases/controls) 2021/2781 1148/1527 654/1044 84/59 135/151
1* 1.00 (Referent) 1.37 (1.17–1.60) 1.68 (1.14–2.48) 2.26 (1.68–3.04)
2† 1.00 (Referent) 1.21 (1.02–1.44) 1.61 (1.05–2.49) 1.87 (1.33–2.62)
3‡ 1.00 (Referent) 1.09 (0.92–1.31) 1.09 (0.92–1.31) 1.64 (1.17–2.30)
White women
No. (cases/controls) 1476/1489 985/1121 359/305 68/36 64/27
1* 1.00 (Referent) 1.41 (1.16–1.72) 1.62 (1.03–2.54) 3.41 (2.03–5.76)
2† 1.00 (Referent) 1.25 (1.00–1.57) 1.56 (0.93–2.59) 2.95 (1.70–5.10)
3‡ 1.00 (Referent) 1.10 (0.88–1.38) 1.49 (0.92–2.41) 2.39 (1.33–4.29)
Black women
No. (cases/controls) 545/1292 163/406 295/739 16/23 71/124
1* 1.00 (Referent) 1.14 (0.91–1.44) 1.71 (0.86–3.38) 1.55 (1.08–2.23)
2† 1.00 (Referent) 1.02 (0.78–1.34) 1.89 (0.91–3.94) 1.27 (0.83–1.97)
3‡ 1.00 (Referent) 0.98 (0.75–1.28) 1.79 (0.86–3.74) 1.21 (0.79–1.85)
Data are given as HR (95% CI) unless otherwise indicated. 25(OH)D indicates 25-hydroxy vitamin D; CVD, cardiovascular disease; HR, hazard ratio; PTH, parathyroid hormone.
*Model 1 adjusted for age, clinical center, and race/ethnicity (for all participants).
†Model 2 further adjusted for family history of CVD, educational levels, alcohol intake, physical activity levels, cigarette smoking status, postmenopausal hormone therapy use, estimated
glomerular ﬁltration rate, body mass index, and seasons of blood draw.
‡Model 3 further adjusted for history of hypertension, history of hypercholesterolemia, history of diabetes mellitus, and statin use.
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differences in the PTH-CVD association may be because of
the relatively small sample size of US black women. Finally,
because the WHI-OS is an all-female postmenopausal cohort,
we were unable to generalize our ﬁndings to men without
consideration of potential biological differences between the
sexes.
In summary, in a large prospective case-cohort study of US
postmenopausal women, we found no signiﬁcant associations
of total, free, and bioavailable 25(OH)D and VDBP with CVD
risk in either black or white women. However, there appears
to be a trend toward increased CVD risk associated with
higher PTH levels among white women, independent of
vitamin D biomarkers as well as known CVD risk factors.
Future longitudinal studies and randomized trials testing
vitamin D supplementation with accurate and well-validated
quantiﬁcation of vitamin D–related metabolites are warranted
to clarify the relationship between vitamin D and CVD
development.
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